We sat down with a trio of experts to discuss the factors currently impacting biosimilar adoption, what reforms are needed to improve it, and what stakeholders can do to help.
The biosimilar market in the United States has had a difficult start since the launch of the first biosimilar in 2015, facing many legal, regulatory, and policy barriers that stall market entry for many FDA approved products, slow down adoption rates and price drops, and discourage physician and patient use of biosimilars. Although some may look at the market and see only its flaws, some experts have hope for the market to change and flourish.
We sat down with Marcus Neubauer, MD, chief medical officer of The US Oncology Network, Kathryn Tong, MBA, vice president of Payer, Pharmacy, Analytics & Transformation for McKesson, and Tommy Pourmahram, vice president of Multi-Source & Analytics for McKesson to discuss some of the factors currently holding back US biosimilar adoption, what reforms are needed to improve it, and what stakeholders can do to help.
To learn more about biosimilar barriers, click here.